The identification of biallelic variants among individuals diagnosed with diabetes in adolescence and individuals with non-insulin-treated diabetes has implications for treatment and genetic testing and indicates that inclusion of ZNF808 to genetic testing panels used for MODY should be considered. This evidence concerns the gene ZNF808 and MODY.